Acquisition by Jay Short of 417000 shares of BioatlaInc subject to Rule 16b-3
| BCAB Stock | USD 0.47 0.01 2.17% |
About 59% of Bioatla's investor base is looking to short. The analysis of the overall investor sentiment regarding Bioatla suggests that many traders are alarmed. The current market sentiment, together with Bioatla's historical and current headlines, can help investors time the market. In addition, many technical investors use Bioatla stock news signals to limit their universe of possible portfolio assets.
Bioatla |
Filed transaction by BioatlaInc Director, 10 Percent Owner, Officer Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Bioatla Fundamental Analysis
We analyze Bioatla's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioatla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioatla based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Bioatla is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Bioatla Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bioatla stock to make a market-neutral strategy. Peer analysis of Bioatla could also be used in its relative valuation, which is a method of valuing Bioatla by comparing valuation metrics with similar companies.
Peers
Bioatla Related Equities
| ACRV | Acrivon Therapeutics, | 4.84 | ||||
| GLUE | Monte Rosa | 3.26 | ||||
| ADAG | Adagene | 2.70 | ||||
| AVTE | Aerovate Therapeutics | 1.55 | ||||
| RZLT | Rezolute | 0.77 | ||||
| ERAS | Erasca | 0.53 | ||||
| IKNA | Ikena Oncology | 0.67 | ||||
| PMVP | Pmv Pharmaceuticals | 1.39 | ||||
| NRIX | Nurix Therapeutics | 1.55 | ||||
| KYMR | Kymera Therapeutics | 2.13 | ||||
| DSGN | Design Therapeutics | 2.41 | ||||
| ANTX | AN2 Therapeutics | 2.56 | ||||
| NAUT | Nautilus Biotechnology | 3.39 | ||||
| FHTX | Foghorn Therapeutics | 3.46 | ||||
| OLMA | Olema Pharmaceuticals | 3.48 | ||||
| IPSC | Century Therapeutics | 3.53 | ||||
| PASG | Passage Bio | 4.92 | ||||
| CCCC | C4 Therapeutics | 5.71 | ||||
| STTK | Shattuck Labs | 7.20 |
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |